Last mentioned: Mar 10, 2026
HIMS Launches GLP-1s
Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
Settlement Reached
Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
FDA Shortage Updates
FDA begins removing specific GLP-1 dosages from the national shortage list.
Settlement & Collaboration
Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.
Supply Stabilization
FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.
Litigation Surge
Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
Hims & Hers GLP-1 Launch
Hims & Hers announces the launch of compounded GLP-1 injections at a significant discount to brand names.
Litigation Wave Begins
Novo Nordisk starts filing lawsuits against medical spas and pharmacies over compounded semaglutide.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Hims & Hers Health and Novo Nordisk have reached a settlement to end their legal dispute over compounded weight loss medications. The agreement transitions the relationship from adversarial litigation to a strategic collaboration, potentially reshaping the telehealth distribution model for GLP-1 drugs.